Astrocytoma, Diagnosis and Treatment. Literature Review
Main Article Content
Abstract
Most primary CNS tumors are astrocytic tumors. Glial tumors are classified according to histological criteria. The WHO classification for primary malignant gliomas in adults includes grades II through IV. Terms for tumors that classify in grade II are astrocytomas (A), oligodendrogliomas (ODG), or mixed gliomas (GM). Grade III tumors are named similarly, and preceded by the word anaplastic, for example, anaplastic astrocytoma (AA), anaplastic oligodendroglioma (ODGA), or mixed anaplastic glioma (GAM). The most malignant form, the grade IV tumor, is designated glioblastoma or GBM. GBMs are diagnosed more frequently than lower grade astrocytomas. The recent GBM classifications reflect the genetic aspects involved in the tumor and have prognostic value.
The most important prognostic factor in malignant gliomas is the histopathological diagnosis of the tumor. The survival of patients with AA is much higher than that of patients with glioblastoma. Other important factors that are associated with the survival of patients with malignant gliomas are the age of the patients, Karnofsky scale, surgery, radiotherapy, and chemotherapy. There is evidence suggesting an association between younger patients and longer survival in adults with supratentorial AA and glioblastoma
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Central Brain Tumor Registry of the United States (CBTRUS). CBTRUS Fact sheet 2016. CBTRUS; 2016. Available at
http://www.cbtrus.org/factsheet/factsheet.html
II. De Robles P, Fiest KM, Frolkis AD, Pringsheim T, Atta C, St Germaine-Smith C, et al. The worldwide incidence and prevalence of primary brain tumors: a systematic review and meta-analysis. Neuro Oncol. 2015 Jun;17(6):776-83.
III. Ostrom QT, Gittleman H, de Blank PM, Finlay JL, Gurney JG, McKean-Cowdin R, et al. American Brain Tumor Association Adolescent and Young Adult Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 20082012. Neuro Oncol. 2016 Jan;18 Suppl 1:i1-i50.
IV. Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro Oncol. 2015 Oct;17 Suppl 4:iv1-iv62.
V. Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep. 2012 Feb;14(1):48-54.
VI. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016 Jun;131(6):803-20.
VII. Verhaak RG1, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al; Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010 Jan 19;17(1): 98-110.
VIII. Cogliano VJ, Baan R, Straif K, Grosse Y, LaubySecretan B, El Ghissassi F, et al. Preventable exposures associated with human cancers. J Natl Cancer Inst. 2011 Dec 21;103(24):1827-39.
IX. Pearce MS, Salotti JA, Little MP, McHugh K, Lee C, Kim KP, et al. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. Lancet. 2012 Aug 4;380(9840):499-505.
X. Berrington de Gonzalez A, Curtis RE, Kry SF, Gilbert E, Lamart S, Berg CD, et al. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol. 2011; 12(4):353-60.
XI. The INTERPHONE Study Group. Brain tumor risk in relation to mobile telephone use: results of the INTERPHONE international case–control study. Int J Epidemiol. 2010; 39(3):675-94.
XII. Hardell L, Carlberg M, Söderqvist F, Mild KH. Case control study of the association between malignant brain tumors diagnosed between 2007 and 2009 and mobile and cordless phone use. Int Jour Onc. 2013; 43: 1833-45.
XIII. Benson VS, Pirie K, Schüz J, Reeves GK, Beral V, Green J, et al. Mobile phone use and risk of brain neoplasms and other cancers: prospective study. Int Jour Epidemiol. 2013; 1-11.
XIV. Lacourt A, Cardis E, Pintos J, Richardson L, Kincl L, Benke G, et al. INTEROCC case-control study: lack of association between glioma tumors and occupational exposure to selected combustion products, dusts and other chemical agents. BMC Public Health. 2013; 13:340.
XV. Ricard D, Idbaih A, Ducray F, Lahutte M, HoangXuan K, Delattre JY., et al. Primary brain tumors in adults. Lancet. 2012; 379:1984-96.
XVI. McCarthy BJ, Rankin KM, Aldape K, Bondy ML, Brännström T, Broholm H, et al. Risk factors for oligodendroglial tumors: a pooled international study. Neuro Oncol. 2011; 13(2):242-50.
XVII. Wang PF, Ji WJ, Zhang XH, Li SW, Yan CX. Inverse association between eczema and meningioma: a meta-analysis. Cancer Cause Control. 2011;22(10):1355-63.
XVIII. Triplett TA, Curti BD, Bonafede PR, Miller WL, Walker EB, Weinberg AD. Defining a functionally distinct subset of human memory CD4 T cells that are CD25pos and FOXP3neg. Eur J Immunol. 2012; 42:1893-905.
XIX. Xie L, Mo M, Jia HX, Liang F, Yuan J, Zhu J. Association between dietary nitrate and nitrite intake and site-specific cancer risk: evidence from observational studies. Oncotarget. 2016 Aug 30;7(35):56915-32.
XX. Mandelzweig L, Novikov I, Sadetzki S. Smoking and risk of glioma: a meta-analysis. Cancer Cause Control. 2009; 20(10):1927-38.
XXI. Kitahara CM, Wang SS, Melin BS, Wang Z, Braganza M, Inskip PD, et al. Association between adult height, genetic susceptibility and risk of glioma. Int J Epidemiol. 2012;41(4):1075-85.
XXII. Shao C, Bai LP, Qi ZY, Hui GZ, Wang Z. Overweight, obesity and meningioma risk: a meta-analysis. PLoS One. 2014;9(2):e90167.
XXIII. Harder T, Plagemann A, Harder A. Birth Weight and Subsequent Risk of Childhood Primary Brain Tumors: A Meta-Analysis. Am J Epidemiol. 2008;168(4):366-73.
XXIV. Tong JJ, Tao H, Hui OT, Jian C. Diabetes mellitus and risk of brain tumors: A meta-analysis. Exp Ther Med. 2012;4(5):877-82.
XXV. Edlinger M, Strohmaier S, Jonsson H, Bjørge T, Manjer J, Borena WT, et al. Blood pressure and other metabolic syndrome factors and risk of brain tumor in the large population-based Me-Can cohort study. J Hypertens. 2012; 30(2):290-6.
XXVI. Ong EL, Goldacre R, Goldacre M. Differential risks of cancer types in people with Parkinson's disease: a national record-linkage study. Eur J Cancer. 2014; 50(14):2456-62.
XXVII. Shiels MS, Cole SR, Kirk GD, Poole C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr. 2009;52(5):611-22.
XXVIII. Qi ZY, Shao C, Huang YL, Hui GZ, Zhou YX, Wang Z. Reproductive and exogenous hormone factors in relation to risk of meningioma in women: a meta-analysis. PLoS One. 2013;8(12):e83261.
XXIX. Qi ZY, Shao C, Zhang X, Hui GZ, Wang Z. Exogenous and endogenous hormones in relation to glioma in women: a meta-analysis of 11 case-control studies. PLoS One. 2013;8(7):e68695.
XXX. Johansson G, Andersson A, Melin B. Recent developments in genetic predisposition syndromes. Act Oncol. 2015; 1-11.